Nordic Nanovector ASA: Annual General Meeting Held

OSLO, Norway, May 30, 2018 /PRNewswire/ -- The Annual General Meeting of Nordic Nanovector ASA (the "Company") (OSE: NANO) was held today on 30 May in Oslo, Norway.

All proposals were resolved by the Annual General Meeting as presented in the notice convening the general meeting distributed on 8 May 2018.

The complete minutes of the Annual General Meeting are attached to this release, and are available on www.nordicnanovector.com.

For further information, please contact:
Malene Brondberg,
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: [email protected]

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--annual-general-meeting-held,c2535237

The following files are available for download:

SOURCE Nordic Nanovector

Related Links

http://www.nordicnanovector.com